Cisneros PE, Serrano PM, Jordán PY, Madrazo GMC

Language: Spanish
References: 23
Page: 523-527
PDF size: 432.88 Kb.

ABSTRACT

Diabetes Mellitus is one of the most frequent metabolic endocrine disorders, which is capable of causing abnormalities in the blood vessels causing complications such as diabetic nephropathy. In the present work, variables were studied that allowed to identify this complication early. A descriptive cross-sectional study was carried out in 61 type 2 diabetic patients, with more than 5 years of evolution, attended in the outpatient department of the endocrinology service of the “Saturnino Lora” provincial teaching hospital in Santiago de Cuba between February 2016 until February of 2017. In the sample studied, the female sex prevailed and the ages between 55 and 59 years of age, 89% of the cases presented high levels of glycemia, in addition 67% metabolic control when presenting high levels of glycosylated hemoglobin. These variables were related to 23% of patients who had altered figures of glomerular filtration rate and 18% with high numbers of microalbuminuria. This allows us to suggest that glomerular filtration and micro albuminuria may be useful in the early evaluation of diabetic nephropathy associated with the parameters of metabolic control of the disease such as glycemia and glycosylated hemoglobin.

REFERENCES

1. Cohen MP. et al. System in the DB/db mouse model of diabetic nephropathy. Exp Nephrol 1998; 6: 226 - 233.

2. Grzeszc Zak W. et al. Angiotensin I converting enzyme gene polymorphisms: Relationship to nephropathy in patients with non - insulin dependent diabetes mellitus. J Am Soc Nephrol 1998; 9: 1664 - 1669.

3. Hoogeveen EK. et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study. Kidney Int. 1998; 53: 203 - 209.

4. Hoogenberg EK. et al. Exogenous norepinephrine induces an enhanced microproteinuric response in microalbuminuric insulin - dependent diabetes mellitus. J Am Soc Nephrol 1998; 9: 643 - 654.

5. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int. 1996, 50: 684 - 692.

6. Ismail, N.; and Becker, B. N. Treatment options and strategies in Uremia: Current trends and future directions. Sem Nephrol 1994; 14 (3): 282 - 299.

7. Regla Carolino ID. et al. Factores de Riesgo en Pacientes con Diabetes Mellitus Tipo 2. Rev Latino-am Enfermagem 2008 março-abril; 16(2): 425-432.

8. Medina López OM. et al. Percepción de salud y su efecto en pacientes con diabetes. Avances en Enfermería. 2009. 12963-13997.

9. Mejía Medina JI. et al. Asociación de factores de riesgo con el descontrol metabólico de Diabetes Mellitus, en pacientes de la clínica oriente del ISSSTE. Revista de Especialidades Médico-Quirúrgicas, 12(2), mayo-agosto, 2007, pp. 25-30.

10. Prieto O. y Vega E. La atención al anciano en Cuba. Desarrollo y perspectivas. La Habana: Editorial de Ciencias Médicas; 2008.

11. Cuba. Ministerio de Salud Pública. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud 2011. La Habana: MINSAP; 2012.

12. Salama Benarrochi I y Adolfo Sánchez G. Factores de riesgo y complicaciones crónicas en el diagnóstico reciente de la diabetes tipo 2. Rev. Cubana Endocrinología; 2010, 12(2):76-81

13. Jacobsen P. et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998; 53: 1002 - 1006.

14. Kelly KD. et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967; 61: 827 - 837.

15. Kimura H. et al. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor - 1 genes in diabetes and macroangiopathy. Kidney Int 1998; 54: 1659 - 1669.

16. Sociedad Brasileña de Diabetes. Tratamiento y seguimiento Diabetes Mellitus- Rio de Janeiros: Editorial Diagrapline, 2007.

17. Stumvoll M, Goldstein BJ and van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005 Apr 9-15;365(9467):1333-46.

18. WHO. World Health Organization. Ginebra, Suiza: WHO, 2011.

19. IDF. International Diabetes Federation. Bruselas, Belgica : International Diabetes Federation, 2011.

20. Hossain P, Kawar B and El Nahas, M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007 Jan 18;356(3):213-5.

21. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587 - 593.

22. Trevisan R, Vedovato M and Tiengo, A. The epidemiology of diabetes mellitus. Nephrol dial Transpl 1998; 13 (Suppl 8): 2 - 5.

23. Farkas G. et al. Albuminuria after fetal pancreatic islet transplantation: a 10-year follow - up. Nephrol Dial Transplant 1998; 13: 2899 - 2904.